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Background: A systematic understanding of chemotherapeutic influence on solid tumours is highly challenging
and complex as it encompasses the interplay of phenomena occurring at multiple scales. It is desirable to have a
multiscale systems framework capable of disentangling the individual roles of multiple contributing factors, such as
transport and extracellular factors, and purely intracellular factors, as well as the interactions among these factors.
Based on a recently developed systems-based modelling framework, we have developed a coupled system in order
to further elucidate the role of drug transport, and its interplay with cellular signalling by incorporating intra- and
extra-vascular drug transport in tumour, dynamic descriptions of intracellular signalling and tumour cell density
dynamics.
Results: Different aspects of the interaction between transport and cell signalling and the effects of transport
parameters have been investigated in silico. Limited drug penetration is found to be a major constraint in inducing
drug effect; many aspects of the interaction of transport with cell signalling are independent of the details of cell
signalling. A sensitivity analysis indicates that the effect of drug diffusivity depends on the balance between
interstitial drug transport and the specific requirement for triggering apoptosis (governed by highly nonlinear
signalling networks), suggesting that the effect of drug diffusivity in such cases must be considered in conjunction
with descriptions of cellular dynamics.
Conclusions: The modelling framework developed in this study provides qualitative and mechanistic insights into
the effect of drug on tumour cells. It provides an in silico experimental platform to investigate the interplay
between extracellular factors (e.g. transport) and intracellular factors. Such a platform is essential to understanding
the individual and combined effects of transport and cellular factors in solid tumour.
Keywords: Drug transport, Drug effect, Intracellular signalling, in silico experimental platform, Systems-based
modelling frameworkIntroduction
The efficacy of chemotherapy is strongly dependent on
the transport of anticancer drugs to tumour cells and
their responses to the administrated drug [1]; both can be
compromised significantly by complexities associated with
cancer, which is a disease of collective dysregulations across
multiple scales.
To exert therapeutic effects, anticancer drugs must
reach tumour cells with a sufficiently high concentration* Correspondence: cong.liu06@imperial.ac.uk
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reproduction in any medium, provided the or[2]. Limited penetration is one of the major causes of
failure of chemotherapy treatment of solid tumours. The
first obstacle to most blood-borne chemotherapeutic agents
is posed by the abnormal and chaotic tumour vasculature,
which limits tumour blood flow and consequently the sup-
ply of drugs and nutrients [3]. After crossing the capillary
wall, anticancer drugs must penetrate through the tumour
interstitium, where drug distribution is determined by the
effectiveness of drug transport by diffusion and convection
as well as drug consumption [2]. Elevated interstitial fluid
pressure in solid tumours hinders convective transport,
rendering diffusion the dominant mechanism for interstitial
drug transport [4]. Drug diffusivity depends strongly on theThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as molecular weight, shape, charge and solubility. Drug
consumption involves drug binding, sequestration and
metabolism, which can be altered by microenvironmental
conditions, such as extracellular matrix composition and
structure, cell packing density and the presence of tumour
acidity [3,5,6].
For most anticancer drugs, it is necessary for drug mole-
cules to transport across cell membranes to reach the
target molecules and interact with them, as a consequence,
triggering cellular signal transduction. Cellular signalling
is one of the important characteristics of every living cell
in that it governs the basic cellular activities by perceiving
and correctly responding to external/internal stimuli.
Anticancer drugs as stress stimuli can regulate/trigger cell
signalling to kill cells or affect their cellular responses (cell
apoptosis, cell proliferation, differentiation and migration),
which might be directly associated with fatal consequences
of cancer [7-9]. The way by which cellular signalling func-
tions is extremely complex as cellular pathways are not
isolated from each other but are interconnected through a
complex network [10]. In particular, highly non-linear
input-output relationships are usually displayed in cell
signalling networks, with a number of emergent properties,
such as adaptive responses and robust switching by positive
feedback [11,12]. It is worth emphasizing that the dynamic
interactions and signal transmission in these chemical
networks control cellular decision making and cellular
responses such as movement, apoptosis etc.
Considerable effort has been devoted to developing
mathematical models to predict drug concentration and
drug effect on solid tumours (for a review, see [13]). Com-
partmental models have been widely adopted for prediction
of temporal profiles of drug concentration in designed
compartments, particularly drug concentration in blood in
pharmacokinetic studies [14-16]. To obtain spatio-temporal
drug distributions in a given tumour geometry, it is ne-
cessary to explicitly account for drug transport (diffusion
or/and convection) [17-19]. After drug concentrations are
obtained, suitable pharmacodynamic models can be used
to predict the effect of drug as a function of drug concen-
tration and/or as a function of time following drug admin-
istration in a phenomenological and empirical manner,
with elaboration of observed data thus neglecting detailed
underlying mechanisms [20-22]. On the other hand, de-
terministic models can be used to describe the tumour
response by assuming a drug concentration-dependent
tumour growth characteristic or tumour death kinetics
[23-25]. Unfortunately, mathematical models addressing
the above mentioned areas have been developed separately;
furthermore, they often bypass a key component that is
the dynamic process of cellular signal transduction. While
all these models are capable of providing certain levels of
insights, none of them offers a transparent and integrateddescription of drug transport and drug effect accounting
for the associated cellular signalling.
In this study, an integrated systems-based mathematical
modelling framework is employed and extended, which
captures the information flow from drug delivery to the
outcome, thus including biological transport processes of
drugs and cellular response and accounting for dynamics
of the relevant signal transduction. This allows us to begin
to probe and elucidate different aspects of the roles and
the interaction of transport and intracellular signalling
dynamics. In a spatially distributed system, intracellular
signalling is triggered in response to heterogeneous drug
stimuli delivered through transport pathways. It must
be emphasized here that drug stimuli are dynamic (being
delivered through complex vascular networks), while drug
transport can be affected by many tissue level features and
intracellular dynamics is highly nonlinear. Finally the
dynamic coupling of these factors is not necessarily uni-
directional. For instance the tissue scale properties and
features could be a potential factor in affecting drug trans-
port; as an example, it is found that apoptosis-inducing
pretreatment enhances drug delivery [26,27]. Furthermore,
with considerable progress in unravelling the intracellular
and intercellular signal transduction in systems biology,
mathematical modelling approaches can begin to go be-
yond empirical and transport centric models to integrate
dynamic descriptions of transport and cellular signalling
for a systematic examination of their interactions.
This paper examines some basic aspects of the inter-
action of transport and cellular dynamics. As a first step,
the model is formulated on a simplified geometry of
tumour vasculature, in which explicit coupling of blood
flow between vascular and interstitial space is incorporated,
along with drug transport. The effects of anticancer drugs
are addressed by integrating the above with dynamics of
intracellular apoptosis signalling. The integrated model is
used to evaluate treatment strategies and to analyse other
factors that may influence the response of tumour cells,
in order to provide insights into the complex interplay
between the different processes involved.
Methods
For mathematical modelling of drug transport, a commonly
adopted approach is to avoid an explicit representation
of the tumour vasculature which, instead, is treated as
a distributed source term in the governing equations
[19,28-31]. In doing so, descriptions of transport processes
are incomplete without accounting for vascular transport
and the spatial relationship between blood vessels and
tumour interstitium. However, incorporating realistic
tumour vasculature geometry is highly challenging, given
the fact that the tumour vasculature is abnormal, irregular
and heterogeneous. Further complexities in evaluating drug
effects are added when dynamic intracellular signalling
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to spatio-temporal drug stimuli and exhibit highly non-
linear dynamics. To obtain clear-cut and transparent
insights into transport mechanisms, cellular signalling
and their interaction, we employ the modelling framework
as an in silico experimental platform which describes a
well-defined tumour-drug system with minimal essential
elements, definite information flow and a controlled source
of variability and heterogeneity. The in silico experimental
platform depicts an idealized tumour with no heterogeneity,
in a simplified geometry. This setup is designed as an initial
effort to contain the minimal components necessary for un-
derstanding the effects of drugs on tumours and elucidating
the effects of transport and cellular factors in a transparent
manner without consideration of other factors.
Computational geometry
The model consists of a single blood vessel surrounded by
the tumour interstitium, which is a simplified representa-
tion also employed in previous studies [32,33]. Although
the geometrical configuration is similar to that of a tumour
cord model [17,18,34], they differ in size in that the present
model mimics the entire transport domain in the tumour
tissue. While the equivalent vessel geometry and the cor-
responding parameters adopted in the model may be an
over-simplification, it is practical and tractable to start with
this simple geometry for the purpose of understanding the
essential interplay between drug transport and drug effect.
Figure 1 depicts the computational geometry and the flow
of information in the model.
Mathematical models
The current modelling framework includes basic descrip-
tions of blood flow, drug transport, intracellular apoptosisFigure 1 Schematic overview of information flow involved in the mod
vascular geometry and (b) diagrammatical representation of the levels of dsignalling and tumour cell density dynamics. The main as-
sumptions are as follows: (1) blood is an incompressible,
Newtonian fluid and the blood vessel is straight and rigid;
(2) the tumour interstitium is homogeneous, with a
uniform distribution of nutrients and pH; (3) tumour cells
are stationary, leading to the assumption that the tumour
interstitium has a fixed outer boundary; (4) all tumour
cells are distributed uniformly, identical (i.e. ignoring cel-
lular variability, stochasticity, and the effects of cell-to-cell
interactions and cell-cycle) and alive initially. These as-
sumptions are made with the understanding that the key
ingredients are reasonably represented in the initial model
and that individual assumptions may be relaxed in subse-
quent studies. Detailed descriptions of each of the elements
are given in the following sections. A brief overview of the
mathematical equations for different regions in the compu-
tational domain is presented in Figure 2, with symbols and
values of parameters defined in Tables 1 and 2.
Tumour blood flow
The model accounts for the coupling between vascular,
transmural and interstitial fluid flow since tumour blood
vessels are highly permeable. Blood flow is assumed to be
steady, which is acceptable here as it is capable of serving
as a fundamental platform to investigate the dynamic be-
haviour of drug transport and intracellular events without
imposing further complexities related to pulsatile blood
flow.
Flow within the blood vessel is governed by the Navier-
Stokes equations:
ρuν⋅∇uν ¼ ‐∇Pν þ ∇⋅ μ ∇uν þ ∇uνð ÞT
 h i
ð1aÞ
∇uv ¼ 0 ð1bÞelling framework. (a) Schematic illustration of the simplest tumour
escription incorporated in the model.
Figure 2 Overview of mathematical descriptions involved in each domain with corresponding boundary conditions. Details of biological
transport (blood flow as well as drug transport), coarse-grained cellular apoptosis signal transduction and tumour cell density dynamics refer to
following subsections.
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velocity vector with subscript v denoting vascular space,
and Pv is vascular blood pressure.
Eqn. 1a and Eqn. 1b are solved subject to the following
boundary conditions:
Pv ¼ PA on Γ v;in ð2aÞ
Pv ¼ PV on Γ v;out ð2bÞ
nv ⋅uv ¼ JF on Γv−i;w ð2cÞ
Fluid motion in the interstitial space is described by
Darcy’s law:
ui∇⋅ KPið Þ ¼ 0 ð3aÞ
∇ui ¼ 0 ð3bÞ
where K represents interstitial hydraulic conductivity,
and ui and Pi are blood velocity vector and fluid pressure
in the interstitium.
The boundary conditions for Eqn. 3a and Eqn. 3b are:
‐ni ⋅ui ¼ JF on Γv−i;w ð4aÞ
Pi ¼ P0on Γ i;edge ð4bÞ
The boundary conditions (BC) described by Eqn. 2a and
Eqn. 2b specify a constant arterial and venous pressure atthe inlet and outlet of the vessel, respectively; BC (2c)
assumes a transmural velocity in the normal direction
(outward) of the blood vessel. BC (4b) assigns the ambient
pressure at all boundaries of the interstitium (except the
vessel wall); BC (4a) prescribes a transmural velocity
normal (inward) to the vessel wall. The transmural velocity,
JF can be calculated using Starling’s law:
JF ¼ Lp PvPiσd πvπið Þð Þ on Γv‐i;w ð5Þ
Where Lp is vascular hydraulic conductivity, σd is osmotic
reflection coefficient, and πv and πi are osmotic pressure
in the vascular and insterstitial space, respectively. As the
contribution of osmotic pressure difference is negligible in
solid tumours, Starling’s law is reduced to
JF ¼ Lp PvPið Þ on Γv‐i;w ð6Þ
Drug transport
Three variables are considered in the drug transport
processes: the intravascular drug concentration (cv), the
interstitial extracellular free drug concentration (cE), and
intracellular drug concentration (cI). Within the blood
Table 1 Parameters and values used in the mathematical models
Parameter Symbol Value Reference
Tumour blood flow
Tumour capillary radius RC 100 (μm) [33]
Tumour interstitium radius RT 1200 (μm) Estimated
Tumour length L 1 (cm) [33]
Blood density ρ 1000 (kg/m3) [32]
Blood viscosity μ 0.004 (Pa∙s) [35]
Vascular hydraulic conductivity Lp 0.36-2.8 × 10
-6 (cm/mmHg∙s) [36]
Tissue hydraulic conductivity K 0.4-2.0 × 10-7 (cm2/mmHg∙s) [36]
Vascular inlet pressure PA 15 (mmHg) [37]
Vascular outlet pressure PV 0 [36]
Ambient pressure P0 0 [36]
Drug transport (Doxorubicin) DE 1.5778 × 10
-6 (cm2/s) [17]
DOX diffusion coefficient
Rate of transmembrane transport V1, V2 0.28 (ng/(10
5cells)/min) [14]
(V1 = V2)
Diffusive permeability for DOX PE 2.778 × 10
-4 (cm/s) [17]
Michaelis constant for transmembrane transport k1 0.219 (μg/ml) [14]
Michaelis constant for transmembrane transport k2 1.37 (ng/(10
5cells)) [14]
Tumour cell density
Initial tumour cell density ct,0 10
6 (cells/mm3) [17]
Tumour cell growth rate a1 0.5 (day
-1) Estimated
Saturation constant in logistic equation b 0.02592 (mm3/(105cells)/day) Estimated
Tumour cell natural decay rate a2 0.24 (day
-1) Estimated
Intracellular signalling:
Bistable switch
Michaelis Menten constants Vf 27 (hr
-1) [38]
Michaelis Menten constants Vr 0.459 (hr
-1) [38]
Michaelis Menten constants Km1 100 [38]
Michaelis Menten constants Km2 0.01 [38]
Kinetic parameter mediating feedback strength kfb 2.927 (hr
-1) [38]
Basal level in the bistable switch p 0.7 Estimated
Parameter mediating input regulation in the bistable switch q 0.3(ng/(105cells))-1 Estimated
Monostable switch
Kinetic parameter reflecting the time scale of the response k 0.432 (hr-1) Estimated
Associated constant kh 1 (ng/(10
5cells)) Estimated
Hill coefficient n 10 Estimated
R1 protein activation rate kf 3.6 (hr
-1) Estimated
R1 protein degradation rate kr 0.144 (hr
-1) Estimated
R1 Threshold for apoptosis switch R1,th 0.9 Estimated
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with negligible reactions (e.g. metabolism, binding/unbind-
ing, uptake). Once extravasated into the tumour intersti-
tium, drug particles penetrate through the intersititum viadiffusion and convection and at the same time they may
be taken up by tumour cells. The drug is treated as a
blood-borne solute and its transport is governed by a
diffusion-convection-reaction equation.
Table 2 Variables and their definitions in the mathematical models
Symbol Definition Symbol Definition
uv Blood velocity vector in vascular domain cv DOX concentration in vascular domain
ui Blood velocity vector in interstitial domain cE Extracellular DOX concentration
Pv Vascular blood pressure cI Intracellular DOX concentration
Pi Interstitial fluid pressure R
Hypothetical downstream intermediate protein in apoptosis
signalling cascade
JF Transmural fluid velocity, determined by Starling’s law R1 Hypothetical protein responsible for triggering apoptosis
Js
Transmural drug flux, determined by Kedem-Katchalsky
equation
ct Tumour cell density
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∂cv
∂t
¼ Dv∇2cvuv ⋅ ∇cv ð7Þ
Where cv refers to drug concentration in the vascular
space, and Dv is drug diffusivity in the vascular space. The
boundary conditions are:
cv¼ S ⋅H Ttð Þ; t> 0 on Γv;in ð8aÞ
nv ⋅ Dv∇cvð Þ ¼ 0 on Γv;out ð8bÞ
Dv∇cvnv þ uvcvnv ¼ J s on Γv‐i;w ð8cÞ
BC (8a) prescribes a pulse injection at the vessel inlet
with a constant intensity S and infusion time T, in which
Heaviside term H() indicates infusion occurs during the
period of t = 0 to t = T. BC (8b) defines a convective flux
at the outlet; BC (8c) sets an outward solute flux across
the leaky wall boundary.
Solute dynamics in the interstitium (Ωi) is governed
by the extracellular and intracellular drug transport.
Extracellular drug concentration:
∂cE
∂t
¼ DE∇2cE  ui⋅∇cE  ct V 1cEcE þ k1 
V2cI
cI þ k2
 
ð9aÞ
Where cE and cI refer to the extracellular and intracellular
drug concentration, respectively, DE is diffusion coefficient
of drug in the interstitium, while ct is tumour cell density.
V1,V2, kE and kI are constants that describe transport across
the cell membrane, in which V1 and V2 are the maximum
rates of transmembrane transport, while k1 and k2 are the
Michaelis-Menten constants for transmembrane transport.
Eqn. 9a describes diffusion, convection of extracellular
drugs and their uptake/pumping out by tumour cells with
the last terms expressed by Michaelis-Menten kinetics. The
boundary conditions are:
DE∇cEni þ uicEni ¼ 0 on Γi;edge ð10aÞ
D∇cEni þ uicEni ¼ J S on Γv−i;w ð10bÞ
BC (10a) describes a no flux condition at the other
boundaries of the interstitium. In the current study, neitherthe surrounding host tissue nor functional lymphatics in
the host tissue are explicitly described. However, it is
possible to incorporate the effect of lymphatic drainage
in the current set up by imposing a mixed boundary
condition at the outer surface. Simulations with both
BCs gave essentially identical results for the stimuli used
here (results not shown). The effect of the host tissue
will be explicitly examined in a future study. BC (10b)
assigns an inward solute flux into the interstitium, which
can be determined by the Kedem-Katchalsky equation:
J s ¼ P cv cEð Þ þ JF 1 σFð Þ△clm⋯△clm ¼ cv cE
ln cv=cE
h i on Γv−i;w
ð11Þ
Where P is drug diffusive permeability across the vessel
wall, σf is osmotic reflection coefficient, Δclm is the log-
mean concentration across the vessel wall, and JF is the
fluid flux across the vessel wall, which is determined by
Starling’s law.
Intracellular drug concentration
The intracellular drug concentration depends on the cor-
responding extracellular drug concentration according to
transmembrane transport. This is given by
∂cI
∂t
¼ V1cE
cE þ k1 
V2cI
cI þ k2 ð12Þ
It is noted that drug binding to plasma proteins (mainly
albumin) is neglected in the current study. In many cases,
the binding/unbinding process is described simply by
first-order kinetics; therefore its effect is relatively simple
in that it reduces the amount of free extracellular drug
available to tumour cells. Incorporation of drug binding
would not alter the system output qualitatively, but would
dramatically increase computational burden. However, it
is essential to take this into account when quantitative
modelling is required or sophisticated binding mechanisms
are involved.
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The modelling of intracellular signalling processes, a
substantial core of systems biology, plays a very important
role in the entire modelling framework as decisions on cell
fate are processed and determined by molecular signalling
networks. It is thus very important to have a dynamic
representation of this in the modelling framework. Given
the complexity of signalling which contains many missing
biological details and unknown parameters, it is essential
to choose an appropriate level of description in the model
to start with, so that the most important known aspects of
the signalling and cellular decision making are included.
Thus, the strategy adopted here is to start with coarse
grained descriptions of the cellular signalling dynamics,
which are capable of representing correctly the nature of
the information flow, and ensuring that the qualitatively
important features of detailed models are accounted for.
We believe that this is more appropriate than starting with
detailed models containing many unknown factors and
other details whose correctness may be difficult to establish.
At the same time, this provides a platform that allows
more detailed mechanistic models to be incorporated in
the future.
When modelling the intracellular processes in response
to chemotherapy, the main process of interest is apoptosis
(programmed cell death) following the administration of
anticancer agents. Based on systems biology investigations
and existing models [39-45], we recognize that two key
features must be reflected by any model regardless of its
complexity. Firstly, some threshold effect must be present;
secondly, the “switch” to apoptosis must be realized in an
irreversible way.
The apoptosis models adopted here are based on the
two types of switches commonly observed in cellular
signalling: bistable and monostable apoptosis switches.
As bistable switches can exhibit irreversibility intrinsically,
they have been used in modelling irreversible cell fate
decision-making in apoptosis [40,43,45]. Generally, positive
feedback (biologically existing in the intracellular caspase
network) and cooperativity (in apoptosome formation)
are regarded as sources of bistability. However, as far as
apoptosis is concerned, it is not obvious whether repre-
senting the irreversible fate (cell death) as a steady state
is necessary or even reasonable (at the cell fate decision
level). It is possible that an irreversible decision is made
when critical cellular events are triggered, from which
there is no turning back. Thus the irreversibility could
result from a simple irreversible reaction, which is kept
under tight control and triggered only under very spe-
cial circumstances [39,41,42]. Noting this, and the fact
that both mechanisms have been discussed in the con-
text of apoptosis, the two models employed in this study
are: (1) a bistable switch with self-contained threshold be-
haviour and irreversibility; (2) a sequential interconnectionof a monostable switch and a downstream irreversible
reaction effect [34].
Bistable switch
dR
dt
¼ V f 1Rð Þ
Km1þ 1Rð Þþ pþ qcIð ÞkfbR 1Rð Þ
VrR
Km2þR
ð13aÞ
Where Km1 and Km2 are the Michaelis-Menten parame-
ters. kfb is a kinetic parameter which parametrizes the
feedback strength. The constants p and q serve to set the
basal level and dynamic range of the module.
Irreversible monostable switch
dR
dt
¼ k c
n
I
khþ cnI
R
 
ð13bÞ
Where n denotes the Hill coefficient, kh an associated
constant in the Hill term, and k is a parameter repre-
senting the time scale of the response.
In both models, R acts as a typical downstream inter-
mediate element along the signal transduction while R1
represents the output responsible for directly triggering
apoptosis.
dR1
dt
¼ kf R 1R1ð ÞkrR1 ð14Þ
Once a threshold of R1 is crossed, cell death is triggered.
Normalised concentrations of molecules R and R1 are
adopted. Two additional points are worth emphasizing
here. Firstly, the actual choice of monostable/bistable
model has a very minor effect, as analysis with other
model variants has led to very similar results. Secondly,
detailed characterization and comparison of monostable
and bistable models demonstrate their similarities and
differences, which provide a basis for their use in contexts
such as this [46].
Tumour cell density dynamics
The equation governing the tumour cell density is described
by a continuous logistic equation [47]:
dct
dt
¼ a1ct  a2ct bc2t ð15Þ
Where a1 is tumour growth rate, a2 is tumour natural
decay rate and b is a saturation constant in the logistic
tumour growth equation.
Eqn. 15 naturally describes the growth and death of cells
with saturating growth effect leading to a finite steady state
(models with some variations have very similar net results:
see [46]). These equations provide an explicit representa-
tion of the key features of interest. Although the popula-
tion balance formalism provides a more comprehensive
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ally highly demanding and can be difficult to handle if
additional cellular complexities are included.
When tumour cells are perturbed by anticancer drugs,
the intracellular apoptosis signalling is initiated, resulting
in cell death at the population level. Since cell density is
described in a continuous, rather than discrete form, trig-
gering of the intracellular threshold is represented by a
sharp fall in growth rate at the population level. Clearly,
the dynamics of the logistic model imply that if the growth
rate becomes sufficiently low, the zero steady state (ct = 0)
would be the only biologically relevant state, indicating
that all cells will eventually die. It should be noted that
computational implementation of this threshold effect is
achieved in a reversible way in the bistable model, but in a
unidirectional (irreversible) way in the monostable model.
Initial conditions
Except for tumour cell density, all other variables are set
to be zero initially. A uniform tumour cell density is
assumed prior to drug injection.
Numerical methods
Computational procedures
All numerical simulations presented in this paper are
implemented in the finite element based software Comsol
Multiphysics. The simulation of blood flow is decoupled
from that of drug transport and tumour cell density by
assuming the velocity field is independent of the drug
concentration field and tumour cell density distribution.
Steady-state simulation of blood flow is carried out first.
Upon obtaining the pressure and velocity fields, drug
transport is resolved by solving the diffusion-convection-
reaction equation. The boundary conditions at the vessel
wall are implemented in accordance with the physical set-
tings in Comsol Multiphysics. With regard to fluid flow,
transmural velocity (JF) is positive in both the vessel and
interstitial domain as it points away from the surface in
the vessel domain, and at the same time, it represents the
inflow to the interstitial domain. JF is set as a variable in
accordance with Starling’s law, which enables the coupling
of the vascular fluid pressure (Pv) to the interstitial fluid
pressure (Pi). For drug transport, an inflow flux is set by
default, which means a negative transmural flux (JS) in the
vessel domain, and a positive flux in the interstitial domain.
Intracellular signal transduction is triggered by the local
intracellular drug concentration, the response of which is
manifested through tumour cell density owing to decreased
tumour growth rate or increased tumour death rate. The
tumour cell density, in turn, affects drug transport.
The equations are discretised and solved on a pre-
generated computational mesh. Mesh sensitivity study is
carried out first to provide mesh independent solutions.
The final mesh consists of 75,000 and 325,000 mappedmeshes for drug transport and tumour cell density,
respectively.
Model parameters
Values of all parameters as well as variables used in the
integrated model are defined in Tables 1 and 2, respectively.
These are extracted from a variety of sources as they span
multiple scales of description and are not available in a
single tumour-drug system. Values for blood flow related
parameters are mainly extracted from similar mathematical
models found in the literature. Doxorubicin (DOX) is one
of the anticancer drugs commonly used in clinics and a
large amount of experimental data is available on its phys-
ical and pharmacokinetics properties; therefore it is chosen
as a representative anticancer drug for parameterization
purpose. Values for tumour growth parameters are chosen
to reflect both the range of steady state, as well as the
appropriate time scale. In the intracellular dynamics, pa-
rameters are not generally available and their values are
determined based on appropriate reflection of the time
scales involved in apoptosis signalling. Further, the
downstream threshold (R1,th) is specially chosen to ensure
complete R1 activation while maintaining the upstream
signal for a sufficient time period. This in turn directly
reflects the cellular behaviour to exposure of drugs for
a sufficient time. Thus our intracellular descriptions
are parameterized so that they are capable of triggering
apoptosis decisions for comparable signals as are seen
experimentally. It should be emphasized that most of
the essential conclusions drawn from this study are not
strongly dependent on the particular numerical choice
of parameters.
Results
In this section, numerical results of blood flow are pre-
sented first, followed by results of drug transport and
distribution. The effect of drug examined in terms of
tumour cell density distribution by considering both bi-
stable and irreversible monostable intracellular apoptosis
models under various pulse drug injections. In addition, a
sensitivity analysis is performed on parameters involved in
drug transport. Results for drug concentration and tumour
cell density are presented in the dimensionless form, which
are normalised by their corresponding reference values:
0.001 μg/mm3 for vascular and extracellular drug concen-
trations, 1 ng/105cells for intracellular drug concentration
and 106 cells/mm3 for tumour cell density.
Blood flow
Axial pressure profiles on the lumen and tissue side of the
blood vessel wall together with the transmural velocity are
presented in Figure 3. It is seen that vascular pressure falls
linearly along the flow direction while interstitial fluid
pressure experiences a sharp rise near the vessel inlet,
Figure 3 Axial distribution of (a) vascular (Pv) and interstitial fluid pressure (Pi) on the capillary wall, (b) transmural velocity.
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entrance effect caused by the discontinuity of pressure
conditions imposed at the vessel inlet and the adjacent
lower boundary of the interstitium. The simulation results
demonstrate that interstitial fluid pressure is strongly
coupled to vascular fluid pressure due to elevated hy-
draulic conductivity normally found in tumour tissues.
Since the pressure difference across the capillary wall
determines the filtration velocity of blood, the latter
(as shown in Figure 3(b)) experiences a sharp fall near
the vessel inlet before declining gradually along the flow
direction as the transmural pressure difference (Pv-Pi)
diminishes.
Drug transport and distribution
Drug transport
Drugs are transported in tumour tissues by diffusion and
convection. The relative importance of diffusion and
convection is measured by Peclet number (Pe) which is
defined as:
Pe¼ Lu
D
where L is the characteristic length, u is a representative
velocity, and D is the diffusion coefficient for a given anti-
cancer drug. Since D is 1.578 × 10-10 m2/s for doxorubicin
(Table 1), the corresponding Pe in the blood vessel is on the
order of 106, suggesting that intravascular drug transport is
dominated by convection.
Drugs extravasate into the tumour interstitium by diffu-
sion and convection, determined by diffusive permeability
P and blood filtration velocity JF. The filtration velocity
shown in Figure 3(b) is of the order of 10-7 m/s, which is
an order of magnitude lower than diffusive permeability
(2.78 × 10-6 m/s) across the vessel wall for doxorubicin,
suggesting that the total transmural flux is dominated by
the diffusive flux in this case.With regard to interstitial drug transport, variations of
Pe (based on local radial velocity) along the radial direction
at three different axial locations are displayed in Figure 4(a).
It shows that Pe is generally of the order of 10-1 and de-
creases along both the radial and axial directions, which
suggests that diffusion is becoming more dominant than
convection and the role of convection may be limited and
confined to a region close to the wall. Furthermore, with
the use of a simple tumour vascular geometry, the effect of
convection can be quantified by comparing cross-sectional
profiles of intracellular drug concentration. As shown in
Figure 4(b), the difference is almost negligible, which con-
firms that diffusion plays a dominant role in interstitial
drug transport.
Drug distribution
The anticancer drug is assumed to be directly injected
into the blood stream at the inlet of the blood vessel in the
form of a pulse, which is an appropriate type of signal as it
represents the time-dependent nature without introducing
further complexity to the analysis of dynamic interactions
between tumours and drugs. For a systemic administration,
a more realistic drug input expressed as an exponentially
decaying function of time [48,49] or based on injection de-
tails could be readily incorporated in the future. Snapshots
of spatial profiles of drug concentration are displayed
in Figure 5, where t = 1.5 h corresponds to the end of
pulse injection and t = 2 h is 0.5 h after drug injection.
In Figure 5(a) drug concentration is uniform in the core
region, while a concentration boundary layer is seen near
the wall with drug concentration on the inner vessel wall
decreasing along the direction of blood flow (z direction).
Figure 5(c) shows that a steep extracellular drug concen-
tration gradient is established close to the vessel wall while
little drug reaches beyond 5RC (RC is the equivalent vessel
radius). As intracellular drug concentration is dependent
on the local extracellular drug concentration, it follows
Figure 4 Role of diffusion and convection in drug transport. (a) cross-sectional profiles of Pe number at various axial positions in tumour
interstitium, (b) quantitative comparison of normalized intracellular drug concentration at axial location z/L = 0.5 with and without convection
under baseline pulse injection at t = 1.5 h (end of injection) and at t = 2 h (0.5 h after injection). Pulse characteristics of baseline pulse: pulse
intensity S = 1, infusion time T = 1.5 h.
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value due to the kinetics of transmembrane transport.
Displayed in Figure 5(b,d,f ) are snapshots of vascu-
lar, extracellular and intracellular drug concentrations at
t = 2 h, half an hour after drug injection. In response to the
sudden termination of drug input, reversal of concentration
gradient is observed in the near wall region inside the
blood vessel and in the interstitium. In this context, the
interstitium acts as a reservoir, from which drugs are
transported back to the blood vessel and eventually leave
the blood vessel by convection. The reverse transport of
drugs is confined to a thin layer close to the vessel wall,
while drugs outside this layer are transported outward in
the radial direction by diffusion and convection. Therefore,
the extracellular drug concentration profile experiences
a rise and reaches a peak before falling off; the same is
observed for the intracellular drug concentration profile.
Drug effect–Tumour cell density distribution
Baseline case
As cell apoptosis is triggered by effective intracellular drug
concentration (above the threshold) which shows little
variation in the axial direction, tumour cell density at any
cross section away from the inlet and outlet effects (e.g.
z/L = 0.5) would be sufficiently representative and can be
used to compare results obtained with different simulation
parameters. Displayed in Figure 6(a) and (b) is the distribu-
tion of tumour cell density under the same pulse injection
for bistable and irreversible monostable switches respect-
ively. As effective drug penetration is confined to the closevicinity of the vessel wall, cell death only occurs in a small
region, leaving most of the tumour interstitial space
unaffected. Similar results are predicted by both bistable
and monostable apoptosis switches. Although intracellular
drug concentration is above its threshold transiently for a
pulse injection, irreversibility of the intracellular apoptosis
module ensures that tumour cell density continues to
decrease in the cell killing region, implying that a single
pulse can only kill cells in a confined region and the width
of tumour cell death region at a specific time point (e.g. the
instant when triggering of apoptosis is completed) is cap-
able of reflecting the drug effect. Therefore, in the following
results, relative tumour cell death regions are presented for
bistable and irreversible monostable apoptosis switches to
illustrate the effects of pulse properties, different pulse
fractionations and other influencing parameters.
Effects of pulse infusion time and intensity
Figure 7(a) shows the effect of infusion time on the width
of tumour cell death region for bistable and irreversible
monostable switches. For both cases, an increase in infu-
sion time causes a moderate extension of the cell killing
region, as a result of improved extracellular drug transport.
A similar effect is found with increased pulse intensity, as
shown in Figure 7(b).
The predicted tumour cell density shown here has a
weaker non-linear response to increases in infusion time
or pulse intensity compared to our previous study [34].
Although the in silico experiments in both studies use
the same basic modelling elements, they differ in the
Figure 5 Snapshots of spatial profiles of drug concentration under baseline pulse injection for bistable switch. Upper panel: vascular
drug concentration at (a) t = 1.5 h, (b) t = 2 h. Middle panel: extracellular drug concentration at (c) t = 1.5 h, (d) t = 2 h. Bottom panel: intracellular
drug concentration at (e) t = 1.5 h, (f) t = 2 h.
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between different elements; the former may significantly
affect the role of drug transport and intracellular signalling
in cell killing. In our previous study [34], the time scale for
transport (diffusion) in a microscopic tumour cord geom-
etry is of the order of seconds, and the results suggest that
transport over such a small time scale plays a less im-
portant role, which results in a more obvious nonlinear
response. However, in the present in silico simulations,
a relatively large tumour interstitium is adopted to
mimic drug penetration through the entire tumour tissue.
Within this context, the time scales for drug transport
(dominated by diffusion) and intracellular signalling are
comparable; therefore, the transport limitation poses a
major constraint in inducing the effect of anticancer drugs
since reactions involved in cellular signalling are triggeredby intracellular drug concentration. It is concluded that
limitations in transport can act as a buffer to reduce the
sensitivity of cell-killing region to changes in the charac-
teristics of stimuli. This is further demonstrated through
the sensitivity analysis on the size of tumour domain
(presented in sensitivity analysis section).
Effects of pulse fractionations
Also examined is the width of tumour cell death region
in response to different pulse fractionations for a fixed
product of pulse strength and pulse duration. Figure 8
shows similar results for different pulse fractionations
except for the case with S = 0.5, T = 4 h, where contrast-
ing results are observed for the bistable and monostable
switch. At this pulse fractionation, the monostable switch
predicts a much wider cell death region than that by the
Figure 6 Tumour cell density under baseline pulse injection. Cross-sectional profiles at z/L = 0.5 of tumour cell density at 10 h display similar
trends for (a) bistable switch, (b) irreversible monostable switch.
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irreversible monostable switches may be due to the follow-
ing reasons: (i) different intracellular apoptosis signalling
dynamics; (ii) different intracellular drug concentrations
determined by interstitial drug transport and reactions or;
(iii) a combination of both. These are examined further as
detailed below.Figure 7 Effect of pulse characteristics on the relative tumour cell de
intensity. (b) effect of pulse intensity under baseline infusion time.Examined first are the intracellular drug concentrations
which act as upstream stimuli to trigger cell apoptosis.
Intracellular drug concentrations at two time points during
the injection are shown in Figure 9. At an earlier time
(t = 2.5 h in Figure 9(a)), intracellular drug concentra-
tion profiles are identical for both cases, but at the end
of injection (t = 4 h in Figure 9(b)), intracellular drugath region at 10 h. (a) Effect of infusion time under baseline pulse
Figure 8 Effect of pulse fractionations on the relative tumour cell death region at 10 h.
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higher than those with the bistable switch, and the region
where intracellular drug concentrations are above the
threshold is wider. Temporal snapshots of tumour cell
density are displayed for both cases in Figure 10. Obvi-
ously, there is no sign of cell death during the injectionFigure 9 Time evolution of intracellular drug concentration under on
z/L = 0.5 of intracellular drug concentration for bistable and irreversible mo
(b) t = 4 h.period for the bistable switch, but for the irreversible
monostable switch cell density starts to decrease at 3 h.
The falling tumour cell density triggers the feedback loop:
decreased cell density leads to reduced drug consumption,
which allows further drug transport and accumulation
inside the cells, thus leading to cell death in the furthere specific pulse fractionation. Snapshots of cross-sectional profiles at
nostable switches under pulse injection S = 0.5, T = 4 h at (a) t = 2.5 h,
Figure 10 Time evolution of tumour cell density under the same pulse fractionation. Snapshots of cross-sectional profiles at z/L = 0.5 of
tumour cell density under the same pulse fractionation as in Figure 9 for (a) bistable switch, (b) irreversible monostable switch.
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tumour cell density is not only demonstrated by the
numerical results shown here, but can also be shown by
performing a non-dimensional analysis of the extracellular
drug transport equation. In addition, Zheng et al. [27] have
provided experimental evidence that drug-induced apop-
tosis facilitates drug penetration in solid tumours. Overall,
we can conclude that there may exist small differences in
response due to differences in intracellular dynamics
(this was also encountered in [46]), and that the simulations
reveal how transport and cellular effect may be coupled
bidirectionally.
Sensitivity analysis
Parameters used in the mathematical models are either
related to drug transport or involved in drug effect. With
regard to drug transport, parameters can be further divided
into three groups: (i) diffusion related parameters, namely
drug diffusivity (D), diffusive permeability (P), (ii) convec-
tion related parameters, such as hydraulic permeability
(Lp), hydraulic conductivity in the interstitium (K), (iii)
tumour geometric parameters, for example, the radius of
blood vessel (RC) and tumour interstitium (RT).
Based on the analysis presented above (in drug transport
section), it is deduced that convection plays a minor role
in the transmural and interstitial drug transport. Since
convection is dependent on hydraulic conductivity Lp and
tissue hydraulic conductivity K, their effects on blood flow
are examined, and both are found to have a marginal
effect on enhancing the transmural velocity (JF) (results
not shown here).
Parameters involved in the intracellular signalling models
are estimated to reflect a time scale and threshold value in
a reasonable range, which agree qualitatively with those
obtained from a cascade of signal transduction. Overall,transparent effects of these parameters are observed as
expected from the coarse-grained intracellular signalling
models. A slower kinetic rate or an elevated threshold
would make it more difficult to trigger apoptosis while in
the opposite scenario, relieving the constraints of apoptosis
may exert a further effect on improving interstitial drug
transport. As the study is oriented towards an integrative
understanding of drug effect with account for mechanistic
drug action, the intracellular signalling models together
with the estimated parameter values adopted in the present
study are sufficient to serve the purpose.
Therefore, the sensitivity study presented here is focused
on how interstitial drug transport may be perturbed by al-
tering diffusion related parameters, namely drug diffusivity
and diffusive permeability, and geometric parameter (the
size of tumour interstitium).
Effect of drug diffusivity
The effect of increasing drug diffusivity (1D, 2D and 10D,
where D is the value of diffusivity in the baseline case)
is studied for two different pulse intensities. It is worth
noting that the influence of drug diffusivity on the tumour
cell density also depends on the intensity of pulse injection.
As shown in Figure 11, increasing drug diffusivity can lead
to reduced cell killing for pulse injection, with failure to
trigger apoptosis at 10 D at normal intensity. Higher drug
diffusivity allows the drug to transport further beyond
the immediate vicinity of the vessel wall, and may help to
establish a homogeneous concentration profile. However,
it is not as simple when examined together with the spe-
cific requirement for apoptosis that the intracellular drug
concentration needs to be sustained above its threshold
for a sufficient length of time. For a smaller amount of
drug, increased drug diffusivity somewhat dilutes the
drug concentration, making it more difficult to satisfy
Figure 11 Effect of drug diffusivity on the relative tumour cell death region at 10 h for bistable switch.
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killing region is reduced. In this context, it would be
favourable if the drug is concentrated in a limited region
to exercise its effect locally. For a higher dosage, the
opposite scenario occurs where the cell death domain is
extended due to improved drug distribution as illustrated
in Figure 11. An obvious increase in the width of cell
death region is found when drug diffusivity is doubled, but
further increase in diffusivity produces little change. The
simulation results indicate that the effect of drug diffusivity
needs to be examined by considering the balance between
interstitial drug transport and the specific requirement of
intracellular apoptosis dynamics, and it is dependent on
the dosage applied. Similar trends are observed when the
monostable apoptosis switch is employed. Overall, we see
from the integrated study that the effect of drug diffusivity
on the outcome is not necessarily as simple as may be
expected by analysing diffusion in isolation.
Effect of diffusive permeability
Drugs extravasate across the blood vessel wall by diffusion
and convection with the former being the dominant mode.
The diffusive transmural flux is determined by the diffusive
permeability of the drug and the concentration gradient
across the vessel wall. Examined here is the distribution of
the tumour cell density for the baseline diffusive perme-
ability (P) and a much higher permeability (10P) under a
given pulse. As shown in Figure 12, an increase in diffu-
sive permeability results in an extension of the cell death
region, but it is still limited to a narrow region close to the
vessel wall even when the diffusive permeability is increasedby ten-fold. This may be attributed to the following:
(1) interstitial drug transport represents an obstacle in
transporting excessive drugs away from the vessel wall;
(2) more drugs are transported back to blood vessel due
to the reversal concentration gradient caused by the ter-
mination of pulse injection.
Effect of the size of tumour interstitium
When the size of the tumour interstitium is reduced by
half, the region of tumour cell death is still confined to
the proximal region to the vessel wall with a marginal
increase as shown in Figure 13. This is explained as fol-
lows. Overall, the reduced size (over a broad spectrum
of tumour size) has negligible effect on interstitial drug
transport during the injection phase. However, during the
post-injection phase, the effect of a reduced tumour size
can be seen in terms of the enhanced convective trans-
mural flux (as a result of increased transmural velocity),
which partially compensates for the negative diffusive flux
back to the blood vessel, and allows more drugs to be
retained in the vicinity, thus leading to enhanced penetra-
tion in the interstitium. With even smaller tumour sizes,
the effect of transport limitation is gradually removed.
Analysis of varying tumour sizes demonstrates that the
effect of drugs is determined by the interaction between
multiple drug transport processes and intracellular signal-
ling dynamics.
Discussion
In this study, the first steps have been taken towards devel-
oping an in silico experimental platform with integration of
Figure 12 Effect of diffusive permeability on the relative tumour cell death region at 10 h.
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and cellular signalling dynamics to provide an overall
framework to systematically evaluate the effect of anti-
cancer drugs on tumour cells. This platform, described by
our model, contains the minimal essential elements to
understand the basic aspects of the interplay between
drug transport and cellular effects. The model set-up
represents an idealized tumour with a well controlledFigure 13 Effect of the size of tumour interstitium on the tumour celenvironment, which is essential for understanding the
interactions of many complicating factors. The tumour
cell density (the output) is determined by the combined
action of drug input (determined by tumour blood flow
and drug transport) and intracellular signalling (involving
non-linear dynamics), when subject to a particular form
of drug stimulus (the input), which is itself determined
by the mode of delivery (not modelled in detail). Basicl death region at 10 h.
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with an aim to create a model system which captures
the information flow from drug delivery to causal effect,
and is capable of serving as a platform to understand
the interplay between transport and extracellular factors
on one hand and cellular features on the other hand.
Drug transport
Rather than treating the tumour blood as a homogeneous
source term in the transport equation, the models describe
tumour blood flow explicitly by coupling vascular blood
flow with the interstitial fluid flow through an elevated
tumour vascular hydraulic conductivity. Drug delivery
is subsequently examined following the same transport
routes. From the simulation results, few differences can be
observed between the drug concentration profiles at differ-
ent axial locations, indicating that intravascular transport
(convection dominant) is not a rate limiting step in the
drug transport processes. Of course it must be borne in
mind that this finding is based on the highly simplified
geometry adopted in this study – a single vessel similar to
the Krogh model. It is acknowledged that a single vessel
model is not always the best model; it fails to capture the
heterogeneous distribution of functional blood vessels in
tumours that result in large avascular regions. However,
the present study focuses on providing essential and
clear-cut insights into drug distribution and drug effect
by conceptualizing the information flow in an integrated
manner. Potentially important factors, such as the com-
plex tumour vascular geometry (or even non-Newtonian
blood rheological properties) may significantly increase re-
sistance to tumour blood flow, thus leading to insufficient
drug delivery through the tumour vasculature and even
more heterogeneous drug distribution in the tumour in-
terstitium. A description of more realistic tumour vascular
network, based on advanced imaging techniques, could
potentially be incorporated into the modelling framework
for more realistic prediction of drug concentration distri-
bution in specific tumours. We also note that to bring
new insights into drug delivery through a complex vascular
network in the tumour, it is necessary to first understand
what the effect is in a simpler vasculature.
The higher vascular permeability normally observed in
tumour tissues facilitates transmural transport of drugs
into the tumour interstitium. However, it is noted that
drug penetration is restricted to the region close to the
blood vessel, with poor drug distribution in the interstitium.
With regard to drug transport into tumour cells, in the case
of the specific anticancer drug selected (doxorubicin), it is
found that the drug is preferentially sequestered in tumour
cells. Therefore, limited drug penetration in the interstitium
is a major difficulty to overcome in order to improve drug
efficacy. Compared to drug diffusion in the interstitium,
drug consumption by tumour cells determined by thetumour cell density plays a dominant role in impairing
interstitial penetration (discussed later). On the other
hand, the heterogeneous drug distribution found in the
spatially distributed system also implies that homogeneous
compartment models may not be sufficient for accurate
predictions of drug efficacy. It is worth pointing out that
the modelling framework developed is not only applicable
to chemotherapeutic agents, but (with minor modifications)
also to oxygen and other endocrine signals, which share the
same transport pathways. Further, interstitial drug transport
may be implicitly affected by cellular responses, such
as the presence of low pH due to the adaptive metabol-
ism towards oxygen starvation, and detoxifying anticancer
drugs due to acquirement of drug resistances. Under-
standing the interplay of such factors is beyond the scope
of this study, but can be built on the existing framework
presented here.
Drug effect
Drug response is evaluated broadly by empirical or mech-
anistic approaches. This study is motivated by the desire
to provide a mechanistic understanding of drug effect by
taking into account the interactions between drugs and
targets, the downstream signalling reactions and ultimately
cell fate decision making. In the current model, apoptosis is
the primary cellular response triggered by anticancer drugs
and dynamic analysis of drug effect is performed at both
cellular and tissue level.
It is important to choose an appropriate level of cellular
effects to be included in the model given the fact that
many of the biochemical details are still unknown (or may
be questionable or may vary between cell types). Coarse
grained descriptions of intracellular process are adopted
here, with a view to qualitatively capture the nature of
signal transduction in the cell and to retain the relevant
input-output signalling characteristics. Future work to in-
clude more biochemical details of the signalling network
(including the detailed dynamics of the caspase network
and its regulation) is needed in order to obtain a more de-
tailed depiction of the cellular signalling and understand
the roles of multiple intracellular regulatory mechanisms.
In the current work, two types of apoptosis modules
with qualitatively distinct dynamics of signal transduction
are included and examined separately: a bistable switch
and an irreversible monostable switch. The two models
are examined to address whether such different dynamic
characteristics at the cellular level would result in different
drug effects at the population level. It has been found that
in most respects the two models predict broadly similar
effects. A related point to be made is that when cellular
signalling is included, one should be very cautious about
claims of validating models from scanty data. The extent
to which signalling models can be distinguished in such a
context is discussed elsewhere [46]. It is worth emphasizing
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models but have the features which would be expected
of all apoptosis models.
Drug transport vs. drug effect
Our analysis reveals that in pulse injections, the drug
killing effect is typically confined to the proximal region
due to limited drug penetration for both types of apoptosis
models (Figures 5,6,7). Our analysis reveals in multiple
ways, the need for incorporating the dynamics of intra-
cellular signalling in mechanistic predictions of drug
effect and investigating drug transport and drug effect
in an integrated manner. Within the present modelling
framework, it is found that interstitial drug transport and
drug effect are strongly coupled: drug-induced pharmaco-
logical effect (apoptosis) can enhance drug penetration in
the interstitium, which constrains the exertion of drug
action. This indicates that an optimal staged treatment
schedule might help to result in a rapid penetration and
the subsequent cell killing in regions further away from
blood vessels.
It is natural to expect that greater diffusivity enhances
drug penetration in the interstitium, resulting in a more
homogeneous distribution of drug concentration. However,
as our analysis shows, it is not necessarily the case that
greater diffusivity would improve drug effect on tumour
cells for a given stimulus. This is due to the specific re-
quirement for apoptosis being triggered and the interplay
between intracellular dynamics and interstitial drug trans-
port. Drug diffusivity in tumour tissues is not only related
to the physiological properties of anticancer agents, i.e. their
charge, size or shape, but also to the structures of tumour
tissues [50]. Therefore, the analysis presented here may
help to refine drug infusion strategies by noting the dif-
ferent effects of drug diffusivity in a drug- and tumour-
specific context.
Conclusions
In this paper, an in silico experimental platform is
employed, which describes the flow of information from
drug delivery to drug effect combining tumour blood flow,
anticancer drug transport and cellular dynamics. Within
the simplified model setting, a series of investigations on
different drug stimuli and parameters is presented, provid-
ing explicit insights into the effect of drug and the interplay
between multiple transport processes and intracellular
signalling dynamics. Although the modelling platform
in the current study is coarse-grained and qualitative in
nature, it is capable of accommodating other mathematical
models and allowing for fine graining and augmented de-
scriptions of individual subprocesses systematically. Quan-
titative understanding of the contributing factors could be
achieved for specific tumour types and specific anticancer
drugs, in conjunction with the relevant experimental dataat multiple scales. The modelling platform can serve as
a computational tool to perform a thorough sensitivity
analysis for the control and optimization of chemothera-
peutic processes.
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